Federal regulators are, this afternoon, holding a public hearing that could shape the future of mental health treatment for more than a million veterans. The FDA's session, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," runs today in Silver Spring, Maryland and virtually, gathering feedback from patients, clinicians, and federal agencies on drugs like psilocybin and MDMA, according to the FDA's own hearing notice.
A five-year federal partnership already underway
The hearing follows a memorandum of understanding signed in July between the Department of Veterans Affairs and Health and Human Services, launching a five-year partnership to research and, if the FDA eventually approves them, deliver psychedelic-assisted therapies to veterans, as reported by Military.com. The agencies say the effort focuses on psilocybin, MDMA, ketamine, and ibogaine for veterans living with serious mental illness, and HHS describes it as a "bold, comprehensive partnership" in its own press release.
Veterans are already in the trials
The policy conversation isn't just theoretical. In early August, the VA launched PIVOT, a five-site clinical trial evaluating psilocybin for veterans with treatment-resistant depression, according to BioSpace. It's one of roughly 20 active VA-backed psychedelic research trials, a research base that's grown as veteran mental health needs have stayed stubbornly high. The trials being cited at today's hearing sit inside a five-year federal roadmap, not a one-time study, which is part of why the FDA convened outside experts and agency partners to weigh in before any drug reaches its desk for approval.
What the FDA is actually weighing
Today's hearing is a formal step in the FDA's process, not a decision. The agency is gathering testimony from patients, clinicians, and psychiatric research centers on how supervised psychedelic-assisted therapy might eventually be delivered if a drug clears the normal approval pipeline, and the hearing supports a broader federal push on serious mental illness treatment ordered earlier this year, according to reporting compiled by BioSpace. Nothing discussed today changes what's available to veterans right now, but it signals that the conversation has moved from the fringes of psychiatry into a formal federal review process, with the VA at the table.
Why this matters for the OWF community
No single treatment is a silver bullet, and psychedelic therapy remains years away from broad approval, if it gets there at all. But the scale of this federal push, spanning the FDA, VA, and HHS, is a sign that veteran mental health is being treated with real urgency. At Operation WarriorFit, we see every day how training for a race gives veterans and first responders a reason to get up, a community that expects them to show up, and a sense of forward motion that complements clinical care rather than replacing it.
If you're a veteran, service member, Guard or Reserve member, or first responder looking for that kind of goal, see if you're eligible for a free race entry.